What drug was routinely given daily to children in the 1960s for childhood kidney disease, such as idiopathic nephrotic syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Historical Treatment of Childhood Kidney Disease in the 1960s

Prednisone (or prednisolone) was the drug routinely given daily to children in the 1960s for childhood kidney disease, particularly idiopathic nephrotic syndrome. This corticosteroid became the mainstay of treatment starting in the 1950s and revolutionized the management of nephrotic syndrome by dramatically reducing mortality from approximately 50% to around 3%. 1, 2

Historical Context and Treatment Evolution

  • Corticosteroids were introduced in the 1950s and quickly became standard therapy for childhood nephrotic syndrome, with oral prednisone or prednisolone administered daily as the primary treatment throughout the 1960s. 1, 3

  • The mortality rate dropped dramatically from frequent deaths due to infections in untreated children to approximately 3% after corticosteroid therapy became standard, with infection remaining the most important cause of death even with treatment. 1

  • Treatment protocols in the 1960s were developed in an ad hoc manner, without the rigorous evidence base that guides modern therapy; the optimal doses and durations were not systematically clarified until decades later through randomized controlled trials. 1

Standard Treatment Regimen

  • The typical daily dosing used prednisone at 60 mg/m²/day or 2 mg/kg/day (maximum 60 mg/day) as a single morning dose, which became the established standard that persists in modern guidelines. 4, 5, 6

  • Most children (approximately 85%) responded to corticosteroids by achieving remission within 4 weeks of daily oral prednisone administration, establishing this as steroid-sensitive nephrotic syndrome. 7

  • However, approximately 70% of children experienced relapses with recurrent episodes of edema and proteinuria, requiring repeated courses of corticosteroid therapy and exposing them to cumulative toxicity. 1

Important Clinical Caveat

  • The major trade-off of corticosteroid therapy was the known adverse effects including obesity, poor growth, hypertension, diabetes mellitus, osteoporosis, and adrenal suppression—side effects that were accepted given the life-saving benefits in an era with limited alternative therapies. 1

  • Steroid-sparing agents such as cyclophosphamide, chlorambucil, and later cyclosporine were not widely available or studied until the 1970s-1990s, making daily prednisone the only viable option for most children with nephrotic syndrome during the 1960s. 2, 8

References

Research

Corticosteroid therapy for nephrotic syndrome in children.

The Cochrane database of systematic reviews, 2004

Research

Update on the treatment of steroid-sensitive nephrotic syndrome.

Pediatric nephrology (Berlin, Germany), 2022

Guideline

Initial Treatment for Nephrotic Syndrome in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of Nephrotic Syndrome in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Management of idiopathic nephrotic syndrome in childhood].

Srpski arhiv za celokupno lekarstvo, 2004

Related Questions

What are the latest treatment guidelines for pediatric patients with nephrotic syndrome?
What is the recommended treatment for a 7-year-old child with frequently relapsing nephrotic syndrome?
What is the initial management for a pediatric patient with nephrotic syndrome, significant proteinuria, and hypoalbuminemia?
Can nephrotic syndrome lead to glaucoma?
What is the definition of steroid-dependent nephrotic syndrome (NS) in patients with a history of nephrotic syndrome?
What is the recommended gabapentin dosing regimen for an adult with restless‑leg syndrome (RLS), including titration, maximum dose, and adjustments for impaired renal function?
How can a 50‑year‑old Filipino male, 78 kg, 170 cm, waist 33 in, with asthma treated with Symbicort (budesonide/formoterol), pre‑diabetes (HbA1c 43 mmol/mol), low‑normal free testosterone (274 pmol/L) and low SHBG (19 nmol/L), reduced heart‑rate variability (39 ms), concentric left‑ventricular remodeling, mild pulmonary hypertension, normal lipid profile, normal renal function, non‑smoker, occasional alcohol use, currently taking metformin 500 mg daily, fish oil, magnesium glycinate, multivitamin and vitamin C 1000 mg, obtain a comprehensive lifestyle plan to improve cardiovascular health, insulin sensitivity, body composition, libido, skin appearance and longevity, including a 10‑year atherosclerotic cardiovascular disease risk estimate and an evidence‑based ranking of supplements?
How does cannabis (marijuana) use affect glycemic control and cardiovascular/respiratory risk in patients with type 2 diabetes?
What is the optimal acute and short‑term management for a 19‑year‑old male, four days after a motor‑vehicle collision, with severe bilateral shoulder‑to‑elbow musculoskeletal pain, left‑knee pressure‑type discomfort and occasional burning/twitching, difficulty dressing, negative X‑rays of right hand and left knee, and a psychiatric history of attention‑deficit/hyperactivity disorder, anxiety, depression, mood swings, anger outbursts, and paranoid ideation who has failed fluoxetine, sertraline, bupropion, atomoxetine, guanfacine, and methylphenidate, is not on escitalopram, uses ibuprofen as needed, has not filled prescribed methocarbamol, and consumes energy drinks and marijuana?
In a 62‑year‑old woman with left lateral hip pain radiating down the leg to the foot and left foot numbness and tingling, what is the most likely diagnosis and appropriate initial management?
What are the recommended dosing adjustments and safety considerations for glipizide in a patient with impaired renal function (eGFR 30–45 mL/min/1.73 m² or <30 mL/min/1.73 m²)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.